Publisher: Renub Research
Published: June 2010
Report Details
“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug),
Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of
the past, present and future prospects. The report has been researched at source globally,
country specific and features latest available data covering:
Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
Region wise Diabetes Health Expenditure and Mortality
Top 10 Countries Diabetes Population and Future Forecast
Top 5 Countries Diabetes Drug Market and Future Forecast
Top 7 Countries Insulin Market and Future Forecast
Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm,
Starlix) data of Past, Present and Future Market
Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog,
Humulin, Apidra, Lantus) data of Past, Present and Future Market
Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past,
Present and Future Market
Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of
Past, Present and Future Market
Research Highlights
USA controls more than 50% of the total Diabetes Drug market share in 2009
Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
China will have the second highest Insulin market share by 2012 replacing Germany
DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3
Billion by 2015.
© Renub Research Page 2 of 18
Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and
cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more
than US$ 4 Billion by 2017
Last year launched Victoza and yet to be launched Exenatide LAR is going to be
blockbuster GLP-1 Agonists
China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
Japan Insulin market is expected to be more than US$ 1 Billion by 2010
Key Drugs Analyzed
Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra,
Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide
Data Sources
Information and data in this report has been collected from various printable and non-
printable sources like Trade Journals, White papers, Online paid databases, News websites,
Government Agencies, Magazines, Newspapers and Trade associations.
© Renub Research Page 3 of 18
Published By
Renub Research
A–116B, Sector–27
Noida – 201301
Phone: +91-120-421-9822, 424-9780 (India)
+1-678-302-0700 (US)
Email: info@renub.com
www.renub.com
© Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-
IV, GLP-1
Renub Research, 2010
Edition 1.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers.
© Renub Research Page 4 of 18
Table of Contents
1. Executive Summary
2. Global Diabetes Market
2.1 Global – Diabetes Drug Market & Future Forecast
2.2 Global – Insulin Market & Future Forecast
2.3 Global – Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)
2.4 Global – Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan,
USA, India)
2.5 Global – Dipeptidyl Peptidase (DPP – IV) Inhibitors Market & Future Forecast
2.6 Global – Glucagon-like Peptide-1(GLP-1) Market & Future Forecast
3. Global – Top 6 Diabetes Drug Brands Market Performance
3.1 Avandia – Past & Present Market
3.2 Actos – Past, Present & Future Forecast
3.3 Amaryl – Past, Present & Future Forecast
3.4 Avandamet – Past, Present & Future Forecast
3.5 Prandin/Novonorm – Past & Present Market
3.6 Starlix – Past, Present & Future Forecast
4. Global – Top 9 Insulin Brands Market Performance
4.1 Novomix – Past, Present & Future Forecast
4.2 Novorapid – Past, Present & Future Forecast
4.3 Levemir – Past, Present & Future Forecast
4.4 Degludec – Yet to be Launched - Future Forecast
4.5 Degludecplus – Yet to be Launched – Future Forecast
4.6 Humalog – Past & Present Market
4.7 Humulin – Past & Present Market
4.8 Apidra – Past, Present & Future Forecast
4.9 Lantus – Past, Present & Future Forecast
© Renub Research Page 5 of 18
5. Global – DPP-IV Inhibitors Brands Market Performance
5.1 Januvia – Past, Present & Future Forecast
5.2 Onglyza – Past, Present & Future Forecast
5.3 Alogliptin – Yet to be Launched – Future Forecast
5.4 Galvus – Past, Present & Future Forecast
5.5 DPP-IV Inhibitors – In Trial Phases
6. Global – GLP-1 Agonists Brands Market Performance
6.1 Byetta – Past, Present & Future Forecast
6.2 Victoza – Past, Present & Future Forecast
6.3 Exenatide LAR – Yet to be Launched – Future Forecast
6.4 Syncria – Yet to be Launched – Future Forecast
6.5 Taspoglutide – Yet to be Launched – Future Forecast
7. Regional Estimates for Diabetes
7.1 Diabetes – Population & Prevalence
7.2 Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.3 Mortality – Due to Diabetes
7.4 North America & Caribbean Region
7.4.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.4.2 Healthcare Expenditure & Type 1 Diabetes
7.4.3 Mortality
7.5 Middle East and North African Region
7.5.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.5.2 Healthcare Expenditure & Type 1 Diabetes
7.5.3 Mortality
7.6 South-East Asian Region
7.6.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.6.2 Healthcare Expenditure & Type 1 Diabetes
7.6.3 Mortality
7.7 European Region
7.7.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.7.2 Healthcare Expenditures & Type 1 Diabetes
© Renub Research Page 6 of 18
7.7.3 Mortality
7.8 South and Central American Region
7.8.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.8.2 Healthcare Expenditures & Type 1 Diabetes
7.8.3 Mortality
7.9 Western Pacific Region
7.9.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.9.2 Healthcare Expenditures & Type 1 Diabetes
7.9.3 Mortality
7.10 African Region
7.10.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.10.2 Healthcare Expenditure & Type 1 Diabetes
7.10.3 Mortality
8. Global – Top 10 Diabetic Countries Performance
8.1 Number of People in Top 10 Diabetic Place
8.2 Prevalence of Diabetes in Top 10 Countries
8.3 India
8.3.1 Diabetes Population & Future Scenario
8.3.2 India – Diabetes Drug Market & Future Forecast
8.3.3 India-Insulin Market & Future Forecast
8.4 China
8.4.1 Diabetes Population & Future Scenario
8.4.2 Diabetes Drug Market & Future Forecast
8.4.3 China Insulin Market & Future Forecast
8.5 United States
8.5.1 Diabetes Population & Future Scenario
8.5.2 Diabetes Drug Market & Future Forecast
8.5.3 Insulin Market & Future Forecast
8.6 Brazil
8.6.1 Diabetes Population & Future Scenario
8.6.2 Diabetes Drug Market & Future Forecast
8.7 Russia
8.7.1 Diabetes Population & Future Scenario
8.7.2 Insulin Market & Future Forecast
© Renub Research Page 7 of 18
8.8 Japan
8.8.1 Diabetes Population & Future Scenario
8.8.2 Diabetes Drug Market & Future Forecast
8.8.3 Insulin Market & Future Forecast
8.9 Germany
8.9.1 Diabetes Population & Future Scenario
8.9.2 Insulin Market & Future Forecast
8.10 Mexico
8.10.1 Diabetes Population & Future Scenario
8.10.2 Insulin Market & Future Forecast
8.11 Indonesia
8.11.1 Diabetes Population & Future Scenario
8.12 Pakistan
8.12.1 Diabetes Population & Future Scenario
© Renub Research Page 8 of 18
List of Figures:
Figure 2-1: Global – Diabetes Drug Market (Billion US$), 2005 – 2009
Figure 2-2: Global – Forecast of Diabetes Drug Market (Billion US$), 2010 – 2013
Figure 2-3: Global – Insulin Market (Billion US$), 2004 – 2009
Figure 2-4: Global – Forecast of Insulin Market (Billion US$), 2010 – 2013
Figure 2-5: Global – Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 –
2009
Figure 2-6: Global – Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India)
(Percent), 2010 – 2013
Figure 2-7: Global – Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India)
(Percent), 2007 – 2009
Figure 2-8: Global – Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA,
India) (Percent), 2010 – 2013
Figure 2-9: Global – DPP – IV Inhibitors Market (Million US$), 2009 – 2015
Figure 2-10: Global – GLP-1 Market (Million US$), 2009 – 2015
Figure 3-1: Global – Avandia Diabetes Drug Brand Sales (Million US$), 2004 – 2009
Figure 3-2: Global – Actos Diabetes Drug Sales (Billion US$), 2005 – 2009
Figure 3-3: Global – Forecast for Actos Diabetes Drug Sales (Billion US$), 2010 & 2013
Figure 3-4: Global – Amaryl Diabetes Drug Sales (Million US$), 2006, 2007, 2009, & Q1 2010
Figure 3-5: Global – Forecast for Amaryl Diabetes Drug Sales (Million US$), 2010 – 2012
Figure 3-6: Global – Avandamet Diabetes Drug Sales (Million US$), 2006 – 2009
Figure 3-7: Global – Forecast for Avandamet Diabetes Drug Sales (Million US$), 2010 – 2012
Figure 3-8: Global – Prandin/Novonorm Diabetes Drug Sales (Million US$), 2007 – 2009
Figure 3-9: Global – Starlix Diabetes Drug Sales (Million US$), 2007 – 2009E
Figure 3-10: Global – Forecast for Starlix Diabetes Drug Sales (Million US$), 2010 – 2012
Figure 4-1: Global – NovoMix Insulin Sales (Million US$), 2005 – 2009
Figure 4-2: Global – NovoRapid Insulin Sales (Million US$), 2005 – 2009
Figure 4-3: Global – Levemir Insulin Sales (Million US$), 2005 – 2009
Figure 4-4: Global – Humalog Insulin Sales (Million US$), 2006 – 2009
Figure 4-5: Global – Humulin Insulin Brand Sales (Million US$), 2006 – 2009
Figure 4-6: Global – Apidra Insulin Sales (Million US$), 2005 – 2009, Q1 2010
Figure 4-7: Apidra – Forecast for Insulin Sales (Million US$), 2009 – 2013
Figure 4-8: Global – Lantus Insulin Sales (Million US$), 2006 – 2009, Q1 2010
Figure 4-9: Global – Forecast for Lantus Insulin Sales (Million US$), 2010 – 2015
Figure 5-1: Global – Januvia DPP-IV Inhibitors Sales (Million US$), 2007 – 2009
Figure 5-2: Global – Forecast for Januvia DPP-IV Inhibitors Sales (Million US$), 2010 – 2017
© Renub Research Page 9 of 18
Figure 5-3: Global – Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US$), 2009 – 2017
Figure 5-4: Global – Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US$), 2011 – 2017
Figure 5-5: Global – Galvus DPP-IV Inhibitors Sale (Million US$), 2007 – 2009
Figure 5-6: Global – Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US$), 2010 – 2012
Figure 6-1: Global – Byetta GLP-1 Sales (Million US$), 2006 – 2009
Figure 6-2: Global – Forecast for Byetta GLP-1 Sales (Million US$), 2010 – 2017
Figure 6-3: Global – Victoza GLP-1 Sales & Future Forecast (Million US$), 2009 – 2017
Figure 6-4: Global – Forecast for Exenatide LAR GLP-1 Sales (Million US$), 2011 – 2017
Figure 6-5: Global – Forecast for Syncria GLP-1 Sales (Million US$), 2013 – 2017
Figure 6-6: Global – Forecast for Taspoglutide GLP-1 Sales (Million US$), 2012 – 2017
Figure 8-1: India – Number of People with Diabetes (Million), 2003, 2007, 2010
Figure 8-2: India – Diabetes Drug Market (Billion INR), 2006 – 2009
Figure 8-3: India – Forecast for Diabetes Drug Market (Billion INR), 2010 – 2014
Figure 8-4: India – Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in
Percent), 2003 & 2007
Figure 8-5: India – Insulin Market (Million INR), 2006 – 2009
Figure 8-6: India – Forecast for Insulin Market (Million INR), 2010 – 2014
Figure 8-7: China – Number of Diabetes Patients (Million), 2003, 2007 & 2010
Figure 8-8: China – Diabetes Drug Market (Billion Yuan), 2006 – 2009E
Figure 8-9: China – Forecast for Diabetes Drug Market (Billion Yuan) 2010 – 2014
Figure 8-10: China – Insulin Market (Million Yuan), 2007 – 2009
Figure 8-11: China – Forecast for Insulin Market (Million Yuan), 2010 – 2014
Figure 8-12: USA – Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010
Figure 8-13: USA – Diabetes Drug Market (Million US$), 2002 – 2009
Figure 8-14: USA – Forecast for Diabetes Drug Market (Million US$), 2010 – 2014
Figure 8-15: USA – Insulin Market (Billion US$), 2003 – 2009
Figure 8-16: USA – Forecast for Insulin Market (Billion US$), 2010 – 2014
Figure 8-17: Brazil – Diabetes Population (Million), 2003, 2007 & 2010
Figure 8-18: Brazil – Diabetes Drug Market (Million US$), 2008 – 2013
Figure 8-19: Russia – Number of Diabetes Population (Million), 2005 & 2010
Figure 8-20: Russia – Insulin Market (Million US$), 2002, 2005 – 2009
Figure 8-21: Russia – Forecast for Insulin Market (Million US$), 2010 – 2014
Figure 8-22: Japan – Number of Diabetes Population (Million), 2003 – 2010
Figure 8-23: Japan – Diabetes Drug Market (Million US$), 2002 – 2009
Figure 8-24: Japan – Forecast for Diabetes Market (Million US$), 2010 – 2014
Figure 8-25: Japan – Insulin Market (Million US$), 1998 – 2009
Figure 8-26: Japan – Forecast for Insulin Market (Million US$), 2010 – 2014
© Renub Research Page 10 of 18
Figure 8-27: Germany – Number of Diabetes Patients (Million), 2003 – 2010
Figure 8-28: Germany – Insulin Market (Million US$), 2004 – 2009E
Figure 8-29: Germany – Forecast for Insulin Market (Billion US$), 2010 – 2014
Figure 8-30: Mexico – Number of People with Diabetes (Million), 2003 – 2005, 2007 & 2010
Figure 8-31: Mexico – Insulin Market (Million US$), 2004 – 2009E
Figure 8-32: Mexico – Forecast for Insulin Market (Million US$), 2010 – 2014
Figure 8-33: Pakistan – Number of Diabetes Patients (Million), 2003, 2007 & 2010
© Renub Research Page 11 of 18
List of Tables:
Table 4-1: Novomix – Forecast for Insulin Sales (Million US$), 2010 – 2030
Table 4-2: Global – Forecast for NovoRapid Insulin Sales (Million US$), 2010 – 2030
Table 4-3: Global – Forecast for Levemir Insulin Sales (Million US$), 2010 – 2030
Table 4-4: Degludec – Forecast for Insulin Sales (Million US$), 2010 – 2030
Table 4-5: DegludecPlus – Forecast for Insulin Sales (Million US$), 2010 – 2030
Table 5-1: DPP-4 Inhibitors –In Trial Phase
Table 7-1: Regional – Estimates for (Number of People with Diabetes, Comparative Diabetes Prevalence
%) (20-79 years), 2010 and 2030
Table 7-2: Regional – Estimates for (Number of People with IGT, Comparative IGT Prevalence %) (20-79
years), 2010 and 2030
Table 7-3: Regional – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-4: North America and Caribbean Region – Population & Adult Population (Million), 2010 & 2030
Table 7-5: North America and Caribbean Region – Number of People with Diabetes & Comparative
Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
Table 7-6: North America and Caribbean Region – Number of People with IGT & Comparative
Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
Table 7-7: North America and Caribbean Region – Health Expenditure for Diabetes (Billion) & Type 1
Diabetes (0-14 Years; Thousand), 2010 & 2030
Table 7-8: North America and Caribbean Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-9: Middle East and North African Region – Population & Adult Population (Million), 2010 & 2030
Table 7-10: Middle East and North African Region – Number of People with Diabetes & Comparative
Prevalence (20-79 Years; Million, Percent), 2010 & 2030
Table 7-11: Middle East and North African Region – Number of People with IGT & Comparative
Prevalence (20-79 Years; Million, Percent), 2010 & 2030
Table 7-12: Middle East and North African Region – Health Expenditure for Diabetes (Billion) & Type 1
Diabetes (0-14 Years; Thousand), 2010 & 2030
Table 7-13: Middle East and North African Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-14: South-East Asian Region – Population & Adult Population (Million), 2010 & 2030
Table 7-15: South-East Asian Region – Number of People with Diabetes & Comparative Prevalence (20-
79 Years; Million, Percent), 2010 & 2030
Table 7-16: South-East Asian Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14
Years; Thousand), 2010 & 2030
Table 7-17: South-East Asian Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-18: European Region – Population & Adult Population (Million), 2010 & 2030
© Renub Research Page 12 of 18
Table 7-19: European Region – Number of People with Diabetes & Comparative Prevalence (20-79
Years; Million Percent), 2010 & 2030
Table 7-20: European Region – Number of People with IGT & Comparative Prevalence (20-79 Years;
Million, Percent), 2010 & 2030
Table 7-21: European Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years;
Thousand), 2010 & 2030
Table 7-22: European Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-23: South and Central American Region – Population & Adult Population (Million), 2010 & 2030
Table 7-24: South and Central American Region – Number of People with Diabetes & Comparative
Prevalence (20-79 Years; Million, Percent), 2010 & 2030
Table 7-25: South and Central American Region – Health Expenditure for Diabetes (Billion) & Type 1
Diabetes (0-14 Years; Thousand), 2010 & 2030
Table 7-26: South and Central American Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-27: Western Pacific Region – Population & Adult Population (Million), 2010 & 2030
Table 7-28: Western Pacific Region – Number of People with Diabetes & Comparative Prevalence (20-79
Years; Million, Percent), 2010 & 2030
Table 7-29: Western Pacific Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14
Years; Thousand), 2010 & 2030
Table 7-30: Western Pacific Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-31: African Region – Population & Adult Population (Million), 2010 & 2030
Table 7-32: African Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years;
Million, Percent), 2010 & 2030
Table 7-33: African Region – Number of People with IGT & Comparative Prevalence (20-79 Years;
Million, Percent), 2010 & 2030
Table 7-34: African Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years;
Thousand), 2010 & 2030
Table 7-35: African Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 8-1: Global – Top 10 Countries Number of People with Diabetes (20-79 age group) (Million) 2010 &
2030
Table 8-2: Global – Top 10 Countries in Prevalence of Diabetes (20-79 age group) (Percent), 2010 &
2030
Table 8-3: India – Forecast for Number of People with Diabetes (Million), 2011 – 2030
Table 8-4: China – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
Table 8-5: USA – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
Table 8-6: Brazil – Forecast for Number of Diabetes Population (Million), 2011 – 2030
Table 8-7: Russia – Forecast for Number of Diabetes Population (Million), 2011 – 2030
Table 8-8: Mexico – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
© Renub Research Page 13 of 18
Table 8-9: Indonesia – Forecast for Number of Diabetes Patients (Million), 2010 – 2030
Table 8-10: Pakistan – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
© Renub Research Page 14 of 18
Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
info@renub.com
Format
Report Title: Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic
Drug), Insulin, DPP-IV, GLP-1
Single User Hard Copy CD – Rom Global Site License
(Email from Publisher) (Mail Delivery) (Mail Delivery) (Multiple User License)
US$ 1,100 US$ 1,250 US$ 1,250 US$ 1,600
For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://renub.com/reports/showdetails.aspx?id=27
2) Order by Wire Transfer:
http://renub.com/reports/wiretransfer.aspx?id=27&pid=1089
To pay by Wire Transfer, please, fill in your contact details in the form below:
© Renub Research Page 15 of 18
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Contact Information
First Name: Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:
© Renub Research Page 16 of 18
3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
A -116B
Sector -27
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-4219-822, 4249-780
For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
© Renub Research Page 17 of 18
About Us
Renub Research is a leading Market Research and Information Analysis Company with
centers at Noida India and Roswell USA. We have more than 7 years of experience especially
in international Business-to-Business Researches, Surveys, Business and Consulting.
Throughout the years we have acquired expertise in most market sectors, including
Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial
Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive,
Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra-competitive markets.
© Renub Research Page 18 of 18